Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma
© Tunici et al; licensee BioMed Central Ltd. 2004
Received: 30 August 2004
Accepted: 06 October 2004
Published: 06 October 2004
Pediatric brain tumors may originate from cells endowed with neural stem/precursor cell properties, growing in vitro as neurospheres. We have found that these cells can also be present in adult brain tumors and form highly infiltrating gliomas in the brain of immunodeficient mice. Neurospheres were grown from three adult brain tumors and two pediatric gliomas. Differentiation of the neurospheres from one adult glioblastoma decreased nestin expression and increased that of glial and neuronal markers. Loss of heterozygosity of 10q and 9p was present in the original glioblastoma, in the neurospheres and in tumors grown into mice, suggesting that PTEN and CDKN2A alterations are key genetic events in tumor initiating cells with neural precursor properties.
Recent data have proposed that brain tumors contain a "core" of stem cells providing them with the potential to grow aggressively, escaping the effects of radiotherapy and chemotherapy [1, 2]. These cancer stem cells were isolated from medulloblastomas or gliomas and grew in vitro as neurospheres, suspended clonal aggregates containing cells with different levels of commitment .
Such observations, derived from pediatric tumors only, did not include data on the in vivo tumorigenicity of cancer stem cells. We have found that neurospheres from an adult glioblastoma (GBM) have the potential to express glial and/or neuronal markers and form highly infiltrating gliomas into the brain of immune-deficient mice.
The neurospheres were derived from three adult brain tumors and two pediatric malignant gliomas (BT1–BT5, see Additional file 1). The neurospheres of BT1, a glioblastoma multiforme (GBM) were studied by flow-cytometry and immunohistochemistry. Under differentiating conditions (EGF-bFGF-LIF withdrawal and FBS addition) nestin expression decreased and BT1 neurospheres expressed high levels of neuronal and astrocytic markers. Remarkably, most of the cells expressed both such markers, suggesting the altered function of a complete differentiation program (see Additional file 2).
To test their neoplastic potential we injected BT1 and BT2 (a central neurocytoma) neurospheres into nude mice. All the mice injected intracerebrally (i.c.) with BT1 neurospheres, but none of those injected subcutaneously (s.c.), developed brain tumors that were lethal after 3, 5 and 6 months, respectively. After 4 months, however, none of the mice injected with BT2 neurospheres developed a tumor. Adherent cells from the same two patients were also injected i.c. and s.c. into nude mice. Two of three mice injected i.c. with BT1 adherent cells, but none of those injected with BT2 cells, developed a brain tumor that were lethal 4 and 5 months after injection, respectively.
Cytogenetic analysis of BT1 neurospheres showed a pseudo-diploid karyotype with monosomy of chromosomes 9, 10, 18, trisomy of chromosomes 19 and 20 and presence of three marker chromosomes. A pseudo-tetraploid clone was also present, resulting from duplication of the pseudo-diploid clone and with the same numerical and structural abnormalities (Fig. 2). The G-banding karyotype of BT1 adherent cells resulted 46, XY. SKY analysis confirmed the numerical changes (monosomies and trisomies) shown by G-banding and allowed to unravel the nature of a the marker chromosomes as a der(3)ins(3;7)(3pter→3q11::7q11→7q22::3q11→3qter).
Three observations are provided by the follow-up of nude mice injected with BT1 cells. First, tumors only developed into the brain and not subcutaneously. Thus, in BT1 the cancer "stem" cells required to be in their niche, i.e. the brain, to develop tumors and the evolution of these tumors resembled closely that of "real" gliomas. The phenotype of such gliomas, however, appeared less aggressive than in the original tumor, possibly because the cancer "stem" cells were conditioned by in vitro passaging and by growth in the brain of immune-deficient mice.
Second, the tumors obtained from neurospheres were completely different from those obtained from established cell lines like U87, 9L, C6 or F98: they grew slower, were highly infiltrating and showed a morphological pattern resembling that of an anaplastic, mixed glioma, but without necrotic areas and palisade cells typical of a GBM (compare Fig. 1C with 1D-E). LOH studies demonstrated the loss of a region chromosome 10q where PTEN is located. PTEN is a critical tumor suppressor gene in GBM but has also an important role in the regulation of neural stem cell proliferation [4–6]. Its loss can therefore be a central event in the neoplastic derangement of brain cancer "stem" cells. We also found combined 9p LOH associated to 10qLOH in S4–5 and in the neurospheres, but not in S2–3, suggesting that 9p LOH is secondary to that on 10q. LOH on 9p suggests the alteration of the important tumor suppressor gene CDKN2A, encoding p16 and p14(ARF). p16 expression is absent or defective in glioblastomas [7, 8] and p16 has an important role in the terminal differentiation of neural precursor cells . Furthermore, p16 is the main target through which Bmi1 regulates neural stem cell differentiation and self-renewal .
Third, LOH on 10q and 9p were present not only in the original tumor and in neurospheres but also in neurosphere-derived gliomas in nude mice. Remarkably, even if adherent cells had a normal karyotype and no allelic imbalance, the derived tumors did show 10q and 9p LOH. This suggests that few adherent cells with these genetic abnormalities escaped our analysis and underwent a positive selection in vivo. These results, therefore, point to PTEN and CDKN2A alterations as critical events in tumor initiating cells, a definition synonymous of cancer stem cells.
The identification of neurospheres from adult brain tumors, and specifically from an adult GBM, is strengthening the case for the importance of cancer "stem" cells in the genesis of these malignancies. A thorough genetic dissection of such cells on a larger scale should give new insights for the therapeutic targeting of these cancer "queen-bee" cells.
We thank Ettore Salsano for collaboration with real-time PCR experiments, Luigi Poliani for helpful suggestions and Francesca Inverardi for help with morphological analysis. This study was partially supported by grants to GF from the Associazione Italiana per la Ricerca sul Cancro and from the Istituto Superiore di Sanita'.
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63: 5821-5828.PubMedGoogle Scholar
- Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003, 100: 15178-15183. 10.1073/pnas.2036535100PubMed CentralView ArticlePubMedGoogle Scholar
- Suslov ON, Kukekov VG, Ignatova TN, Steindler DA: Neural stem cell heterogeneity demonstrated by molecular phenotyping of clonal neurospheres. Proc Natl Acad Sci U S A. 2002, 99: 14506-14511. 10.1073/pnas.212525299PubMed CentralView ArticlePubMedGoogle Scholar
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943View ArticlePubMedGoogle Scholar
- Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G: PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene. 1998, 16: 541-545. 10.1038/sj.onc.1201689View ArticlePubMedGoogle Scholar
- Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H: Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 2001, 294: 2186-2189. 10.1126/science.1065518View ArticlePubMedGoogle Scholar
- Giani C, Finocchiaro G: Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res. 1994, 54: 6338-6339.PubMedGoogle Scholar
- Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC: Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 2002, 62: 5551-5558.PubMedGoogle Scholar
- Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA: Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002, 1: 269-277. 10.1016/S1535-6108(02)00046-6View ArticlePubMedGoogle Scholar
- Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ: Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 2003, 425: 962-967. 10.1038/nature02060PubMed CentralView ArticlePubMedGoogle Scholar
- Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De Fraja C, Vescovi A, Cattaneo E, Finocchiaro G: Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med. 2000, 6: 447-450. 10.1038/74710View ArticlePubMedGoogle Scholar
- Bissola L, Eoli M, Pollo B, Merciai BM, Silvani A, Salsano E, Maccagnano C, Bruzzone MG, Fuhrman Conti AM, Solero CL, Giombini S, Broggi G, Boiardi A, Finocchiaro G: Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol. 2002, 52: 842-845. 10.1002/ana.10405View ArticlePubMedGoogle Scholar
- Schrock E, Veldman T, Padilla-Nash H, Ning Y, Spurbeck J, Jalal S, Shaffer LG, Papenhausen P, Kozma C, Phelan MC, Kjeldsen E, Schonberg SA, O'Brien P, Biesecker L, du Manoir S, Ried T: Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet. 1997, 101: 255-262. 10.1007/s004390050626View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.